Drug discovery and development – Page 10
-
ResearchArtificially evolved enzyme tackles tricky cross coupling
Directed evolution on the metalloenzyme cytochrome P450 creates a catalyst for making macrocyclic antibiotics
-
BusinessProtective treatment for Covid-19 makes minimal impact
Limited uptake of antibody combination for vulnerable patients, while demand for antivirals seems to be slowing
-
OpinionWhy AlphaFold won’t revolutionise drug discovery
Protein structure prediction is a hard problem, but even harder ones remain
-
ResearchTeixobactin’s two pronged antibiotic attack mechanism revealed
Understanding of formation of deadly supramolecular structures could help build improved antimicrobials
-
OpinionMay cause side effects
The dose makes the poison, but understanding unwanted drug interactions is complicated
-
ResearchAntigen-carrying adjuvants activate both adaptive and innate immunity
Aluminosilicate nanoparticles promote ion perturbation, pyroptosis and enhanced immunity in a cancer model
-
BusinessCalifornia advances plans to make its own insulin
Governor commits $100 million to develop low-cost insulin and build manufacturing facility to strengthen drug’s supply chain
-
OpinionAlzheimer’s, amyloid and abandoned antibodies
Biogen’s aducanumab is stumbling into obscurity. Where does that leave the amyloid hypothesis?
-
ResearchMolecular machine drills holes in antibiotic-resistant bacteria killing them
Bacteria aren’t able to develop resistance against nanomotor’s deadly action
-
NewsNew questions raised over Sputnik Covid vaccine results point to fraudulent practices
Analysis comparing Sputnik results with five other Covid vaccines finds phase 3 trial outcome is highly improbable
-
BusinessSoapbark branches out to fill essential role in vaccine recipes
The soapbark tree has long been used in traditional medicines, but is now coveted for some of our newest vaccines
-
ResearchLight-activated cancer treatment uses tumour-targeting enzymes to cut side effects
Enzymatic activation of a photosensitive prodrug in cancerous cells shows promise in mice
-
ResearchBreaking bacteria’s genetic silence to synthesise antibiotics that evade resistance
Prospecting in bacterial genomes offers hope in search for new antimicrobial drugs
-
BusinessWhat is the future of Covid-19 pharmaceuticals?
Firms anticipate long-term markets for prevention and treatment
-
FeatureThe incredible antibodies of sharks, llamas and camels
Sharks and llamas share a strange quirk of their immune systems. Hayley Bennett finds out how their ‘nanobodies’ could help us tackle Covid and a host of other diseases
-
ResearchAI tool finds green ways to turn chemical waste into drugs
Circular approach for industry by-products considers environmental, economic and geographic aspects to rank predicted routes for real-world applications
-
WebinarSpeed up process development by making more from your offline and online data
Learn how the biotechnology R&D team at Clariant uses statistical modelling techniques to speed up the process development of their bio-ethanol product
-
BusinessUK takes subscription approach for new antibiotics
Decoupling payment from prescriptions helps preserve last-line antibiotics and encourage R&D
-
NewsUK’s non-profit vaccine manufacturing centre sold off before opening
Pharmaceutical firm Catalent buys government-backed facility near Oxford
-
FeatureA decade of CAR-T cell therapy
Nina Notman looks at the revolutionary treatment already taking on cancer, now aiming for wider use